Potential therapeutic strategies to target gut microbiota in hepatocellular carcinoma by Amedei, Amedeo
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2019;8(5):527-529 | http://dx.doi.org/10.21037/hbsn.2019.09.04
The gut microbiota (GM) is an assorted ecosystem, 
composed of viruses, fungi, protozoa, archaea, and especially 
bacteria, which exist in a definite symbiosis between 
each other and the host (human) as well. Increasing data 
document that GM plays key parts in human physiology, 
taking part in the digestive process, vitamin B synthesis, 
promotion of angiogenesis and nerve functionality, and 
notably in the maturation and modulation of the immune 
system. In addition, it is commonly known and accepted 
that the GM has an impacting role in different pathological 
disorders, such as gastrointestinal, hepatic, respiratory, 
cardiovascular and endocrine (1). In fact, different studies 
confirmed that the GM is involved in the pathogenesis 
of different pathologies, including inflammatory and 
irritably bowel syndrome, autism, depression, obesity, 
atherosclerosis, colorectal carcinoma, infectious and non-
infectious chronic liver diseases (2-6).
The GM as a “virtual metabolic organ” makes axis with 
various extra-intestinal organs, such as brain (the most 
relevant), lung, cardiovascular, kidneys and the liver (7). 
The gut-liver axis is the result of a close (anatomical and 
functional) bidirectional interaction of the gastrointestinal 
tract and liver, primarily by the portal circulation. Moreover, 
an intricate network of interactions, which encompass 
metabolic, immune, and neuroendocrine crosstalk between 
them, controls the symbiotic connection between the liver 
and the GM (2). The gut-liver axis has been associated 
with the pathogenesis of numerous chronic liver diseases, 
comprising liver cirrhosis, chronic hepatitis B/C (CHB and 
CHC), non-alcoholic fatty liver disease (NAFLD), non-
alcoholic steatohepatitis (NASH), and the hepatocellular 
carcinoma (HCC) (8), that is the third most common cause 
of cancer-related mortality worldwide (9).
To date, numerous data from animal models and human 
studies suggest a GM role in the HCC development. In 
particular, intestinal dysbiosis was found in patients with 
liver cirrhosis and HCC and in mice after diethylnitrosamine 
(DEN) administration. 
As well reported by Wan and El-Nezami (10), there are 
three potential mechanisms through which the gut-liver axis 
can favour the HCC pathogenesis: 
(I) Via leaky gut, endotoxemia and toll-like receptor 
(TLR). Above all, high circulating lipopolysaccharide 
(LPS) levels were shown in both HCC animal 
models and patients with HCC. These enlarged 
values are likely attributed to increased intestinal 
permeability and so the amplified bacterial 
translocation. 
(II) Via dysbiosis and bacterial metabolite production. 
It is explicative a recent study where dietary or 
genetic obesity modifies the GM, increasing the 
deoxycholic acid (DCA) levels. DCA is a bacterial 
metabolite that causes DNA damage and stimulate 
the production of various inflammatory and 
tumour-promoting factors in the liver, thereby 
endorsing HCC development in a mouse model 
(after exposure to chemical carcinogen). 
(III) Via immunomodulation. It is postulated that the 
Editorial
Potential therapeutic strategies to target gut microbiota in 
hepatocellular carcinoma
Amedeo Amedei1,2
1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; 2Sod of Interdisciplinary Internal Medicine, Azienda 
Ospedaliera Universitaria Careggi (AOUC), University of Florence, Florence, Italy
Correspondence to: Amedeo Amedei. Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.  
Email: aamedei@unifi.it. 
Comment on: Wan MLY, El-Nezami H. Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. Hepatobiliary Surg Nutr 
2018;7:11-20. 
Submitted Aug 29, 2019. Accepted for publication Sep 09, 2019.
doi: 10.21037/hbsn.2019.09.04
View this article at: http://dx.doi.org/10.21037/hbsn.2019.09.04
529
Amedei. Therapeutic targeting of GM in HCC528
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2019;8(5):527-529 | http://dx.doi.org/10.21037/hbsn.2019.09.04
high amount of intestinal IL-17 may involve in the 
HCC development. 
So, notified the importance of the link with the GM and 
owing to a lack of pharmacological preventive strategies and 
limited chemotherapeutic options for the HCC treatment, 
the authors suggest that the therapeutic GM modulation 
by probiotics might represent an innovative approach to 
prevent the HCC progression. In addition, they analysed 
and discussed the various mechanisms by which the 
probiotics can have anti-cancer effects. The probiotics can 
show anti-cancer effect, directly modulating the microbiota, 
but they can exert also indirect actions through different 
pathways, such as immune modulation, anti-inflammatory 
and anti-pathogenic activities, improving the intestinal 
barrier function and so decreasing the bacterial translocation, 
as well as reducing tumor formation and metastasis.
Regarding the anti-HCC probiotics’ functions, the 
authors focusing on the major four: 
(I) Binding/adsorption of carcinogens. Animal studies 
have demonstrated that both AFB1 toxicity and 
bioavailability are reduced after administration of 
probiotics. 
(II) Improvement of intestinal barrier function. The 
probiotics could remodel the GM composition, 
suppressing the outgrowth of Gram-negative bacteria 
and improving the intestinal barrier, preventing 
translocation of endotoxins. In this way, the cancer-
related inflammation was decreased in the liver. 
(III) Modulation of short-chain fatty acids (SCFA) 
production. Some probiotics’  strains (e.g., 
Bifidobacteria and Lactobacilli) can modify the GM 
composition, chancing the production of SCFA and 
favouring the production of SCFA that may reduce 
the risk of developing cancer, including HCC. 
(IV) Regulation of Th17 response. The probiotics can 
cause shifts in the GM composition toward specific 
beneficial bacteria, for example, Prevotella and 
Oscillibacter. These bacteria are famous to secrete 
anti-inflammatory metabolites, which are able 
to contrast the Th17 polarization, favouring the 
differentiation of regulatory T cells (Tregs) in the 
intestinal mucosa.
In conclusion, after these premises and having argued the 
anti-cancer role of probiotics, Wan and El-Nezami declared 
that the GM manipulation may represent an innovative, safe 
and low-cost strategy to prevent or treat HCC. In addition, 
they specified that more basic studies as well as human 
clinical trials in GM evaluation and correctly selected useful 
bacterial strains are required to gain the acceptance of the 
broader medical community and to consider the possibility 
to use probiotics as an alternative (or supportive, suggest 
me) anti-cancer treatment. 
In summary, I agree with the authors and I firmly 
convinced that the GM modulation might have important 
applications for future treatments in the oncological field. 
In fact, as previously reported (11) the multifaceted rapport 
between the GM and human beings do concern not only 
empirical aspects, but require the necessity to adopt novel 
concepts/perspectives in order to be appropriately applied, 
especially in their therapeutic implementation.
Nevertheless, the probiotics are one of the different 
approaches to modulate the GM and given the complexity 
of the microbiota ecosystem, it is hard to think that one or 
few bacterial strains can resolutely change the composition 
of the microbiota (unless there are definite deficiencies of 
specific strains). Therefore, I believe that the probiotics may 
be essentially used in preventive/supportive manner while 
other approaches could be more effective in editing the 
microbiota, such as antibiotics, but especially bacteriophages 
and fecal microbiota transplantation (FMT). Currently 
the FMT is used for the treatment of Clostridioides difficile 
infection (CDI) but there are clinical trials for different 
diseases, including one of my group regarding patients with 
amyotrophic lateral sclerosis (ALS) (12). 
About the phage therapy, a recent study demonstrated 
in a mouse model that phage predation not only directly 
impacts susceptible bacteria, but also leads to cascading 
effects on other bacterial species via interbacterial 
interactions, changing the gut metabolome (13). These 
data suggest the potential impact of gut phages on the host, 
with implications for their therapeutic use to precisely 
edit the microbiome. In addition, some types of CRISPR-
Cas systems could be used to modify the genome of gut 
microorganisms and bacteriophages, to specifically eliminate 
members of the microbiome or to control gene expression, 
modulating the production of metabolites/proteins. In 
conclusion, these tools offer stimulating opportunities to 
explore the intricate interplay between GM members and 
our bodies, and open novel roads for the development of 
drugs targeting the microbiome (14). 
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